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Background: Phase-contrast (PC) MRI is a feasible and valid noninvasive technique to measure renal artery blood flow,
showing potential to support diagnosis and monitoring of renal diseases. However, the variability in measured renal blood
flow values across studies is large, most likely due to differences in PC-MRI acquisition and processing. Standardized acqui-
sition and processing protocols are therefore needed to minimize this variability and maximize the potential of renal PC-
MRI as a clinically useful tool.
Purpose: To build technical recommendations for the acquisition, processing, and analysis of renal 2D PC-MRI data in
human subjects to promote standardization of renal blood flow measurements and facilitate the comparability of results
across scanners and in multicenter clinical studies.
Study Type: Systematic consensus process using a modified Delphi method.
Population: Not applicable.
Sequence Field/Strength: Renal fast gradient echo-based 2D PC-MRI.
Assessment: An international panel of 27 experts from Europe, the USA, Australia, and Japan with 6 (interquartile range
4–10) years of experience in 2D PC-MRI formulated consensus statements on renal 2D PC-MRI in two rounds of surveys.
Starting from a recently published systematic review article, literature-based and data-driven statements regarding patient
preparation, hardware, acquisition protocol, analysis steps, and data reporting were formulated.
Statistical Tests: Consensus was defined as ≥75% unanimity in response, and a clear preference was defined as 60–74%
agreement among the experts.
Results: Among 60 statements, 57 (95%) achieved consensus after the second-round survey, while the remaining three
showed a clear preference. Consensus statements resulted in specific recommendations for subject preparation, 2D renal
PC-MRI data acquisition, processing, and reporting.
Data Conclusion: These recommendations might promote a widespread adoption of renal PC-MRI, and may help foster
the set-up of multicenter studies aimed at defining reference values and building larger and more definitive evidence, and
will facilitate clinical translation of PC-MRI.
Level of Evidence: 1
Technical Efficacy Stage: 1
J. MAGN. RESON. IMAGING 2020.
A DECREASE IN RENAL BLOOD FLOW (RBF) isarguably one of the first signs of renal damage in a range
of renal disorders.1,2 Traditionally, measurement of RBF
involves infusion of para-aminohippurate and blood samples
regularly taken over a time-course of several hours. Clearly,
this method is cumbersome and cannot differentiate single
kidney blood flow.3 These are the main reasons why classical
measurement of RBF is hardly used in clinical practice.
Phase-contrast magnetic resonance imaging (PC-MRI) is a
noncontrast-enhanced MRI technique that allows the deter-
mination of blood velocity and flow in a specific vessel during
the cardiac cycle within a few minutes.4 With no need for
contrast agents that are potentially associated with risks for
renal patients,5 PC-MRI is a feasible and valid noninvasive
technique to reliably measure RBF and a number of deriva-
tive hemodynamic parameters, for each kidney separately, in
both healthy volunteers and patients with renal or vascular
disease.6 Moreover, in PC-MRI RBF is measured directly, in
contrast to alternative MRI techniques such as arterial spin
labeling (ASL), where total renal perfusion depends on label-
ing efficiency and the T1 of blood and tissue, which are typi-
cally estimated. In short, a 3D vascular survey is first acquired
to adequately plan the 2D PC-MRI acquisition plane. Phase
and magnitude images are then acquired for each renal artery,
and RBF is computed by multiplying the renal artery area by
mean blood velocity inside the vessel during the cardiac cycle
(Fig. 1),6 using the following formula:
Q = 60×A×v
where Q is the total blood flow rate through the renal artery
(in mL/min), 60 is a conversion factor (from seconds to
minutes), A is the total vessel area (in cm2), and v is the aver-
age velocity (averaged over the cardiac cycle and vessel area, in
cm/s). Renal PC-MRI has been validated in humans both techni-
cally and biologically, also showing good repeatability and
reproducibility.6–8 Despite renal PC-MRI not being routinely
used in the clinic, there are a number of clinical studies showing
its potential to support diagnosis and monitoring of renal diseases,
in particular chronic kidney disease,9 renovascular disease,10,11
and autosomal dominant polycystic kidney disease.12,13 In healthy
subjects, the variability in RBF values across studies is large, likely
due to differences in PC-MRI acquisition and processing, pre-
cluding the definition of normative ranges and warranting the
need for common protocols facilitating standardization across cen-
ters and comparability of different study results.6
The open and growing renal MRI network “Magnetic
Resonance Imaging Biomarkers for Chronic Kidney Disease”
(PARENCHIMA) is an Action funded by the European Coop-
eration in Science and Technology (COST, CA16103, www.
renalmri.org), which aims at boosting the use of renal MRI bio-
markers to improve the management of patients with renal dis-
ease. Within this network there is an ongoing effort to improve
standardization in the acquisition and analysis of clinical renal
MRI data. In line with these aims, the COST Action
PARENCHIMA has initiated a consensus project to define
expert-based technical recommendations to harmonize renal
MRI acquisition and analysis protocols.14 Technical recommen-
dations have been recently published for renal blood
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oxygenation-level-dependent (BOLD),15 diffusion-weighted
imaging (DWI),16 T1 and T2 mapping,
17 and ASL18 MRI
methods. This study, as part of this standardization effort, pro-
poses a set of technical recommendations for renal 2D PC-MRI
acquisition, analysis, and reporting, based on consensus by an
international panel of experts in the field that could establish a
clear reference baseline for future developments.
Materials and Methods
Technical recommendations on subject preparation, scanner hard-
ware, PC-MRI acquisition, postprocessing, and reporting of results
were obtained by consensus, following a previously published con-
sensus defining process.14 First, an international panel of experts
with first-hand experience in renal PC-MRI was formed, as
described below. All members were signed up to the panel at their
own request, and deliberately consented to participate in the consen-
sus process, which was clearly laid out prior to starting. Then con-
sensus was generated by an approximate Delphi method where, at
each iteration, participants were invited to respond to a survey
including an anonymous summary of the previous responses.14,19,20
The Panel of Experts
The panel of experts was as large and representative as possible, both
in terms of geographical distribution, background, and expertise in
order to develop global and comprehensive technical recommenda-
tions. The panel included experts with first-hand experience in renal
PC-MRI as evidenced by a previous track record of publications
and/or ongoing research. First, PARENCHIMA members with a
publication record and/or research activities in renal PC-MRI since
2005 were invited to join the expert panel. Then experts
FIGURE 1: Schematic representation of 2D phase-contrast magnetic resonance imaging (PC-MRI) acquisition and processing. (a) A
single axial, coronal, and sagittal 2D slice of the 3D vascular survey, showing hyperintense arteries, to illustrate planning of the 2D
PC-MRI acquisition plane, (b) Acquired phase and magnitude images depicting the renal artery in the center. A circular ROI was
drawn on the magnitude images and copied to the phase images. The temporal sequences show the evolution of the phase signal
inside the vessel in the cardiac cycle, which is graphically shown in (c), a graph showing the mean and max velocity in the ROI during
the cardiac cycle. PC-MRI data were acquired using the recommended acquisition protocol in the University Medical Center Utrecht,
the Netherlands and in the ASST Papa Giovanni XXIII, Bergamo, Italy.
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participating in similar consensus initiatives on renal DWI,16
BOLD,15 ASL,18 and T1 and T2 mapping
17 were contacted and
invited if they had research experience in renal PC-MRI. Last, to
further expand the panel of experts, every effort was made to invite
at least one researcher or corresponding author from each group con-
tributing to the renal PC-MRI literature since 2005, as surveyed pre-
viously.6 When responding to the questionnaires, panelists were
asked to list their background/specialty, as well as to specify their
expertise in renal PC-MRI usage. The international panel included
27 experts working in 11 countries from four continents (Europe,
America, Asia, and Australia) and with multidisciplinary back-
grounds as follows: physics (15/27, 55%), radiology (8/27, 30%),
engineering (2/27, 7%), cardiology (1/27, 4%), and mathematics
(1/27, 4%). Renal PC-MRI was mainly used by the panel members
for research studies (25/27, 93%), followed by technical develop-
ment and/or validation (7/27, 26%), and clinical practice (6/27,
22%). The panel members had 6 (interquartile range 4–10) years of
experience in 2D PC-MRI. The panel was formed at the start of the
consensus process and remained constant throughout the process.
All respondents are listed as authors of this article.
The Consensus Process
The consensus process took place between January and April 2020.
An initial (first round) survey was prepared by the panel co-chairs
(A.d.B. and A.C.) based on the literature and taking advantage of a
recently published systematic review and statement paper on renal
PC-MRI.6 Information included in published renal PC-MRI studies
was used to identify key preparation, acquisition, and processing pro-
tocol parameters. The first-round survey consisted of 56 questions
with multiple-choice responses, with the possibility to abstain or to
provide a long form answer (see Supplementary Material). Partici-
pants were prompted to explain the reasoning behind their choices
in a comment section following each item and to suggest questions
for inclusion in the second-round survey. The second-round survey
was drafted to include proposed statements informed by the
responses and comments from the first round. In the second-round
survey (see Supplementary Material), which consisted of 60 state-
ments, panelists were asked to either agree or disagree with each of
the proposed statements; in the case of insufficient experience in any
of the statements, panelists were asked to refrain from answering.
Both round surveys were administered to the panel members via an
online form (Google Forms). Respondents were encouraged to
answer the questionnaires based on published evidence and best
practices as reflected in the literature, which might deviate from the
method they use in their clinical practice.
The consensus process was focused on 2D PC-MRI. In the
first-round survey there was an additional section on 4D flow
(3D Cine PC MR angiography) to determine the amount of exper-
tise on 4D flow in the panel.
With a view to acquiring PC-MRI as part of a multi-
parametric renal MRI protocol, subject preparation statements were
consistent with those used in previous renal MRI consensus initia-
tives on BOLD,15 DWI,16 T1 and T2 mapping,
17 and ASL.18
Interpretation of the Survey Results
A “traffic light” system was adopted to issue recommendations
based on the degree of consensus achieved by the experts on the
individual statements. “Green light” (consensus) was defined as at
least 75% unanimity in responses to a question. An “orange light”
was defined in the case where the responses showed clear preference
(60–74% agreement) without reaching consensus. A “red light”
was defined when there was no clear preference by the experts
(50–59%); in those cases, no recommendation was possible. For
each statement, the percentage of abstentions was also recorded.
Agreement and disagreement percentages were computed excluding
abstentions. However, the percentage of abstentions for each item




The response rate for both surveys was 100%. The 60 final
consensus statements are listed in Table 1. Expertise in 4D
flow was limited to 8 out of 27 (29.6%) panel members.
Therefore, 4D flow was excluded from further analysis.
The experts showed substantial agreement on renal 2D
PC-MRI data acquisition and analysis protocols: for most of
the consensus statements, the percentage of agreement was
much higher than the preestablished threshold (≥75%), with
100% agreement in 18/60 (30%) of the statements. Consen-
sus was not reached in 3/60 of the statements, where, how-
ever, the experts showed clear preference. Overall, for the
57 statements reaching consensus, the agreement and absten-
tion levels were on average 91.6 ± 9.5% and 7.8 ± 9.4%,
respectively.
Final Recommendations
Considering the literature trends, consensus views, and prefer-
ences, the final key recommendations were developed
(Table 2).
RECOMMENDATIONS REGARDING PATIENT
PREPARATION. The panel advises against strict control of
diet and hydration [Table 1: R1.1–1.5]. Three panelists
commented that extensive control of diet and hydration
state are hardly feasible in clinical practice. However, sub-
jects should be scanned in normal hydration status [R1.2]
and should be asked to avoid salty- and protein-rich meals
before acquisition [R1.5], since hydration state, salt, and
protein intake are known to influence renal blood flow.21,22
It is recommended to measure hematocrit, (estimated) glo-
merular filtration rage (GFR), and blood pressure since this
enables derivation of relevant renal physiology parameters
[R9.8]. These include filtration fraction (ratio of the GFR to
the renal plasma flow, measuring the proportion of fluid fil-
tered by the kidneys into the renal tubules), renal vascular
resistance (ratio of mean arterial pressure to mean RBF,
measuring the degree to which the blood vessels of the kid-
neys impede the flow of blood through them), and renal
plasma flow (RPF, blood plasma delivered to the kidneys
per unit time, computed as23:
4
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TABLE 1. Final Consensus Statements on Renal 2D Phase-Contrast MRI, Formulated by an International Panel of








1.1 Subjects are required to fast before the scan 38 62 19
1.2 Subject should be scanned in a normal hydration status when clinically
appropriate
91 9 12
1.3 Subjects are required to follow a controlled and standardized salt
intake before the scan
24 76 35
1.4 Diet should otherwise be controlled (apart from salt and fasting) 0 100 27
1.5 Subjects are not required to fast, but it is recommended to advise
them to avoid salty and protein-rich meals before acquisition
86 14 15
2. Scanner hardware
2.1 2D phase contrast MRI can be performed on both 1.5 and 3T 100 0 8
2.2 The body coil should be used as RF transmitter coil 96 4 0
2.3 A clinical phased array coil should be used as receive coil with the max
available receive channels
100 0 4
3. Preparation of acquisition
3.1 B0 shimming is required 79 21 8
3.2 B1 shimming is recommended 68 32 23
3.3 A vascular survey should be performed for planning of the 2D phase
contrast MRI
88 12 4
3.4 The vascular survey should be performed at least in coronal and
transverse direction to ensure perpendicular planning
100 0 0
3.5 Addition of a sagittal direction to the vascular survey is recommended 64 36 12
3.6 Which vascular survey is used depends on experience and availability
in the center, it is suggested to use either IFDIR or TOF MRA in case
of a noncontrast MR examination
96 4 8
4. Planning of 2D phase contrast MRI acquisition
4.1 2D phase contrast MRI should be scanned perpendicular to the vessel
of interest
96 4 0
4.2 2D phase contrast MRI is preferably planned on the renal arteries 100 0 0
4.3 If planning on the renal arteries is not possible due to limited size or
tortuosity of the vessels, it is suggested to measure blood flow through
the aorta above and below the branches of the renal arteries
95 5 19
4.4 2D phase contrast MRI should be planned on a linear part of the renal
artery without apparent vascular abnormalities (stenoses, string-of-
beads), preferably not too close to the aorta (roughly >1 cm)
100 0 4
4.5 In case of planning on the aorta, the upper acquisition plane should be
placed below the superior mesenteric artery and above the renal arteries.
89 11 31
4.6 In case of planning on the aorta, the lower acquisition plane should be
planned below the main renal arteries, below any accessory renal arteries
and above the ovarian/testicular arteries
100 0 19
5








4.7 All renal arteries should be measured independently, including
accessory renal arteries. However, if multiple renal arteries happen to run
in parallel and perpendicular planning on both is possible, they can be
measured in a single acquisition
96 4 0
5. Acquisition of 2D phase contrast MRI
5.1 Fast gradient echo with cartesian readout is currently recommended as
a base sequence
100 0 0
5.2 A slice thickness of 3–6 mm is recommended 100 0 4
5.3 The acquired in-plane voxel size (not the reconstructed voxel size) is
recommended to be below 1.5 mm
96 4 0
5.4 The field of view (FOV) should be large enough to avoid foldover
artifacts, with the smallest dimension preferably above 200 mm
96 4 0
5.5 The acquired matrix size is related to FOV divided by acquired voxel
size. The acquired matrix size is recommended to be larger than
128 × 128
96 4 0
5.6 The shortest possible TE should be used, with a max value of 4 msec 100 0 0
5.7 The shortest possible TR (Siemens and GE: echo spacing) should be
used, with a max value of 10 msec
96 4 0
5.8 A flip angle between 10–30 degrees is recommended for noncontrast
acquisitions
100 0 0
5.9 Parallel imaging is recommended when there is need to shorten
breath-hold duration
96 4 8
5.10 Halfscan or partial Fourier is not recommended, but if it is required
to shorten breath-hold duration, limited halfscan factors can be used
(above 0.7)
100 0 15
5.11 To obtain reasonable SNR, a bandwidth lower than 500 Hz/pixel is
recommended
96 4 4
5.12 Fat suppression is not required 91 9 8
6. Choice of VENC
6.1 It is recommended to choose a fixed VENC throughout the study, but
check the examination for phase wrapping and repeat with higher
VENC if necessary
96 4 0
6.2 For the aorta, a VENC of 150 cm/s is recommended for healthy
volunteers
95 5 12
6.3 For the aorta, for populations with suspected vascular disease a VENC
of 200 cm/s is recommended
94 6 35
6.4 For the renal arteries, a VENC of 100–120 cm/s is recommended for
healthy volunteers
96 4 0
6.5 For populations with suspected vascular disease a higher VENC of
150 cm/s can be indicated
86 14 15
6









7.1 Cardiac synchronization should be performed either using
retrospective or prospective triggering
100 0 0
7.2 Cardiac triggering should preferably be performed with ECG 83 17 4
7.3 The number of time points acquired should be maximized within
reasonable scan time, with at least 20 time points per cardiac cycle
92 8 0
7.4 Breath-holding is preferred for respiratory compensation. If impossible,
respiratory triggering can be used
91 9 8
7.5 The max breath-hold time should preferably be below 20s 100 0 0




8.1 Background phase correction should be performed using stationary
voxels during postprocessing if the scanner does not perform it
automatically
95 5 23
8.2 Post-hoc motion correction (ie. image registration, either rigid or
affine) is recommended
75 25 19
8.3 A (semi-)automated approach for ROI selection is recommended,
however if that is not available, manual ROI selection can be used
100 0 0
8.4 If ROIs are drawn manually, it is recommended to draw them on each
magnitude frame
92 8 4
8.5 In case of manual ROI selection, it is recommended to draw a circular
ROI
80 20 0
8.6 In case of artifacts in a single time frame the affected frame should be
removed
96 4 0
8.7 In case of artifacts in multiple time frames, the entire examination
should be discarded
86 14 12
8.8 Phase unwrapping should be performed if necessary 85 15 23
9. Reporting of results
9.1 It is recommended to report renal blood flow per kidney (so if
multiple renal arteries are present, the blood flows through these arteries
are combined)
100 0 0
9.2 Average mean velocity is defined as average velocity over time averaged
over voxels. It is recommended to report the average mean velocity per
vessel
96 4 8
9.3 It is recommended to report the groupwise mean and standard
deviation of the average mean velocity per vessel
96 4 8
9.4 The peak systolic velocity is defined as max velocity over time averaged
over voxels. It is recommended to report the peak systolic velocity per
vessel
83 17 4
9.5 It is recommended to report the groupwise mean and standard
deviation of the peak systolic velocity per vessel
83 17 4
7
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RPF =RBF 1 − hematocritð Þ
RECOMMENDATIONS REGARDING RENAL 2D PC-MRI
ACQUISITION. The panel recommends using a fast gradient
echo (Philips, Best, Netherlands: T1 fast field echo [FFE],
Siemens, Erlangen, Germany: fast low angle shot [FLASH];
General Electric, Milwaukee, WI: spoiled gradient recalled
[SPGR]) sequence [5.1] with Cartesian readout on a 1.5 or
3T scanner [R2.1]. To minimize scan time, echo time, and
repetition time (Philips: repetition time [TR], Siemens and
General Electric: echo spacing) should be kept as low as pos-
sible (see Fig. 2 for an example pulse sequence diagram)
[R5.6–5.7]. For a further reduction of scan time, parallel
imaging is preferred over partial Fourier (Philips: halfscan,
Siemens: half Fourier; General Electric: fractional number of
excitations [NEX]) [R5.9;5.10]. Resolution must be high
enough to obtain multiple voxels in the renal artery and low
enough to retain a sufficient signal-to-noise ratio (SNR), in-
plane resolution below 1.5 [R5.3], and through-plane resolu-
tion of 3–6 mm [R5.2]. Acquisition should be performed in
a single breath-hold, preferably in breath-out to improve
reproducibility, with cardiac triggering using electrocardio-
gram (ECG) [R7.4–7.6]. In case breath-holding is impossible
(for example, in uncooperative patients), respiratory triggering
can be used [R7.4]. Care has to be taken to place the acquisi-
tion plane orthogonal to the artery of interest [R4.1]. There-
fore, a high-quality vascular survey in at least two (transverse
and coronal) or preferably three orthogonal directions is nec-
essary for planning [R3.3–3.5]. Different noncontrast-
enhanced magnetic resonance angiography (MRA) sequences
can provide data of sufficiently high quality, including time-
of-flight (TOF) MRA and inflow-dependent inversion recov-
ery (IFDIR)24 [R3.6].
Measuring renal blood flow directly on the renal arteries
is recommended [R4.2;4.4]. If that is not possible due to
tortuosity or small size of the renal arteries, one can instead
opt to measure blood flow in the aorta above and below the
branching of the renal arteries [R4.3]. In that case, care has
to be taken that no other arteries (especially the superior mes-
enteric artery and the testicular/ovarian arteries) originate
between the upper and lower acquisition plane [R4.5–4.6].
Furthermore, all accessory renal arteries should be included
[R4.6]. The aortic inflow/outflow method correlates reason-
ably well with RBF measured directly on the renal arteries.6
By default, one acquisition is performed per renal artery
with an acquisition (breath-hold) time below 20 seconds
[R7.5–7.6]. Accessory renal arteries should be measured sepa-
rately, unless multiple arteries happen to run in parallel and
can be measured simultaneously [R4.7].
The panel recognizes that there is not a single optimal
velocity encoding (VENC) for the acquisition of renal 2D
PC-MRI. In general, a VENC of 100–120 cm/s for the renal
artery in healthy volunteers is recommended [R6.4], which
should be increased to 150 cm/s in subjects with suspected
vascular disease to reflect the higher peak velocities reached in
(atherosclerotic) vascular disease [R6.5].25 Since peak flow
velocity in the aorta is increased,26 a higher VENC is rec-
ommended for the aorta [R6.2–6.3]. One fixed VENC
should be chosen throughout a study; however if phase wrap-
ping is observed, the acquisition should be repeated with a
higher VENC [R6.1]. Alternatively, phase unwrapping can be
performed (see below) [R8.8].
RECOMMENDATIONS REGARDING RENAL 2D PC-MRI
POSTPROCESSING. In addition to the use of breath-holding
during the acquisition, the panel recommends post-hoc
motion correction (ie, image registration, either rigid or
affine) [R8.2]. Due to motion of the arteries during the car-
diac cycle, images may be misaligned despite the use of
breath-holding. For region of interest (ROI) selection, a








9.6 If possible, it is recommended to measure (estimated) GFR, blood
pressure and hematocrit as well to be able to calculate filtration fraction,
renal vascular resistance and renal plasma flow, respectively
100 0 8
9.7 The parameters listed in Table 3 (left) should at least be reported ≥80a <20 0
9.8 The parameters listed in Table 3 (right) are recommended to be
reported as well
≥76a <24 0
Agreement and disagreement percentages were computed excluding abstentions, and were color-coded as follows: green = consensus
(≥75%), orange = preference (≥60%), and red = indeterminate.
aMinimum percentage of agreement for each of the listed items.
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majority of panelists used a threshold-based approach on
either the magnitude (47%) or the phase image (21%), or
alternatively a method based on the flow profile (26%). If no
software is available for (semi-)automated processing, it is rec-
ommended to draw circular ROIs manually on each magni-
tude image frame, which eliminates the need for post-hoc
motion correction by image registration, taking care of cover-
ing the whole lumen to ensure capturing the whole velocity
spectrum [R8.4–8.5]. In case of artifacts affecting a single
time frame, that frame should be removed [R8.6]. When arti-
facts affect multiple time frames, the entire examination
should be discarded [R8.7].
RECOMMENDATIONS REGARDING REPORTING OF
RESULTS. Total renal blood flow per kidney should be
reported in milliliters per minute (average renal blood flow
over the cardiac cycle). In case of multiple renal arteries, the
flow through the main and accessory arteries should be com-
bined [R9.1]. Additionally, it is recommended to report the
groupwise mean and standard deviation of the average mean
velocity (average velocity over time averaged over voxels) and
peak systolic velocity (max velocity over time averaged over
voxels) [R9.2–9.5]. In Table 3, all relevant information to
report is listed [R9.7–9.8].
The data in Fig. 1 were acquired using the rec-
ommended protocol.
Discussion
This consensus article provides a set of technical recommen-
dations on renal 2D PC-MRI acquisition, processing, and
reporting to promote standardization across centers, and thus
foster the comparability of different study results and the defi-
nition of reference values. Furthermore, the current work pro-
vides guidelines to new researchers and clinicians approaching
renal PC-MRI for the first time.
Technical Recommendations
The substantial agreement reached on almost all consensus
statements suggests that renal PC-MRI, being in use in clinical
TABLE 2. Key Recommendations on Renal 2D PC-MRI
Acquisition, Processing, and Reporting
Patient preparation Normal hydration state,
avoid salty- and protein
rich meals
Field strength 1.5 or 3T
Sequence Fast gradient echo
Vascular survey Noncontrast-enhanced MRA
Orientation of imaging
plane
Perpendicular to renal artery
In-plane resolution <1.5 mm
Slice thickness 3–6 mm




As short as possible, <10
msec









ROI placement Preferably semi-automated,
alternative manual
Reporting Flow per kidney, mean and
peak velocity per vessel
Groupwise reporting Mean and standard deviation
MRA = magnetic resonance angiography; TR = repetition time
(or echo spacing in General Electric and Siemens); TE = echo
time; VENC = velocity encoding; ECG = electrocardiogram;
ROI = region of interest.
FIGURE 2: Pulse diagram of the recommended sequence with typical timings of the shot interval (Siemens and General Electric:
repetition time), repetition time (Siemens and General Electric: echo spacing), and echo time.
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research for more than 20 years, is amenable to standardization
and could be sufficiently mature to enter clinical practice.
RECOMMENDATIONS REGARDING PATIENT
PREPARATION. Renal blood flow has long been known to be
influenced by (protein-rich) meals and hydration state.21,22 Post-
prandially, renal blood flow can be increased by up to 50%,22
depending on the composition of the meal. Additional research
is needed to determine to what extent control of diet and hydra-
tion state is necessary to ensure comparability and repeatability
of renal 2D PC-MRI measurements. Yet practical limitations
may lead to difficulties in controlling diet or salt intake.
RECOMMENDATIONS REGARDING ACQUISITION.
Pragmatically, the panel agreed to recommend different
VENC values for the renal artery and the aorta in healthy
and vascular-impaired populations, based on experience and
information in the literature on peak velocity in these
populations.25 26 However, additional research is needed to
determine the optimal VENC in different populations. Paral-
lel imaging has been shown not to affect flow estimates and is
therefore preferred above partial Fourier.27,28
RECOMMENDATIONS REGARDING PROCESSING. (Semi-)
automated ROI selection was recommended over manual
selection, since it is probably more repeatable, but there was
no preference for a specific method. Not all vendors offer
semiautomated ROI selection for 2D PC-MRI and in-house-
developed tools are currently widely used. There is an urgent
need for development of standardized and widely available
software and for research comparing (semi-)automated
approaches of ROI selection to manual selection. In Ref. 6 an
overview of (semi-)automated ROI selection methods for
renal PC-MRI is provided.
During postprocessing, background phase correction
should be performed as described previously.29 On most clin-
ical systems, this is performed automatically by the scanner
software.
RECOMMENDATIONS REGARDING REPORTING.
Currently, the panel recommends reporting RBF in units of
ml/min. In case of RBF comparison between groups (rather
than to assess changes on individual level), it might be appro-
priate to correct RBF for body surface area, for example,
using the Du Bois formula.30
Issues Reaching Consensus
Experts were divided on the requirement to fast before the
scan, as discussed above. Moreover, consensus was not
reached on two statements related to preparation of PC-MRI
acquisition. Most experts recommended B1 shimming in
addition to B0 shimming, but the percentage of agreement
did not reach the consensus threshold, likely due to limited
data available and lack of experience on this issue, proved by
a high percentage of abstention. Finally, the experts were
divided on the value of performing a sagittal vascular survey
in addition to the coronal and transverse vascular survey, with
most being in favor. Despite the correct placement of the
PC-MRI acquisition slice determining the accuracy of RBF
measurements and derivative parameters, no evidence in the
literature about a sagittal vascular survey actually improving
PC-MRI acquisition planning was found. However, a 3D
vascular survey can be reformatted by most MR acquisition
software in any other plane, so this is a minor issue.
TABLE 3. Relevant Information to Report in 2D Renal




liquid and salt intake)
Artifact handling
Scanner vendor Background phase
correction
Field strength Matrix size
Base sequence Partial Fourier/halfscan
factor
Geometry (Voxel size,

























aIn case of cardiac triggering the actual breath-hold duration
should be reported.
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PC-MRI as Part of a Renal MRI Protocol
Multiparametric renal MRI protocols are likely to benefit
from the combination of PC-MRI with other promising renal
MRI techniques (such as BOLD,31 DWI,32 T1 and T2
mapping,33 and ASL34) providing complementary informa-
tion on renal microstructure and function in a multi-
parametric approach,35 and thus enabling a complete
assessment of the normal and diseased kidney. Considering
the acquisition of multiparametric renal MRI data in a single
session, patient preparation and scanner hardware guidelines
should be consistent across measures.
Our recommendations on scanner hardware are in line
with consensus guidelines for renal BOLD,15 DWI,16 ASL,18
and T1 and T2 mapping,
17 suggesting that both 1.5T and 3T
are adequate field strengths for renal MRI acquisition, despite
multiparametric studies being performed more frequently at
3T. Higher field strength provides increased SNR but, con-
versely, entails greater field inhomogeneities. Moreover, PC-
MRI guidelines recommend a radiofrequency transmitter
body coil and a clinical phased array receive coil with the
maximum available number of channels, in line with both
renal ASL18 and T1 and T2 mapping
17 guidelines.
Regarding patient preparation for 2D PC-MRI acquisi-
tion, the recommendation to scan subjects in a normal hydra-
tion status when clinically appropriate is in line with
consensus guidelines for all other renal MRI modalities.15–18
As discussed above for 2D PC-MRI, also for BOLD, DWI,
ASL, and T1 and T2 mapping evidence on the influence of
fasting, diet, and salt intake is currently not sufficient for con-
clusive statements. This is reflected by the lack of consensus
on the requirement to fast in the consensus guidelines for all
those renal MRI modalities. More systematic studies are
needed to investigate whether fasting, diet, and salt intake
control could have an effect on renal multiparametric MRI
measurements.
Although acquisition of the 2D PC-MRI datasets takes
two breath-holds (longer in case of respiratory triggering),
planning can be challenging and time-consuming. A vascular
survey is crucial to aid in planning and to assure perpendicu-
lar planning of the acquisition plane to the renal arteries. A
vascular survey of sufficient quality can be performed within
one 20-second breath-hold up to 5 minutes (respiratory trig-
gered), depending on the field strength, technical feasibility,
and patient cooperation.
Technical Recommendations, Outlook, and
Generalizability
All major vendors of MR systems offer 2D PC-MRI and the
protocol as it is recommended in this article should be feasi-
ble on all clinical systems. Nevertheless, the recommendations
capture the current consensus of a wide panel of international
experts on renal 2D PC-MRI and are not intended to slow
innovation or development in the field in any way. They
should not be seen as definitive, but are rather expected and
encouraged to be updated over time as more data and techni-
cal developments become available. In particular, it is
expected: 1) future technical developments to further improve
renal PC-MRI acquisition, for example, flow phantoms as
possible methods to calibrate PC sequences36 and non-
Cartesian parallel imaging37 and compressed sensing38 to
reduce MRI data acquisition time; 2) increasing expertise in
4D flow, a promising acquisition method allowing extraction
of blood velocity and flow information in any plane, rather
than in a single double oblique 2D slice,7 and increasing evi-
dence that could lead to the development of technical recom-
mendations specific to 4D flow; and 3) improvements in the
analysis pipelines, especially in the selection of the ROI and
in motion correction. In order to be as generalizable as possi-
ble, consensus statements were formulated in vendor-neutral
terms. Future efforts are needed to make vendor-specific
acquisition protocols compliant with the recommendations
available through public repositories, to foster their adoption
in clinical research, and ultimately in clinical practice. Never-
theless, even without public repositories it should be possible
to develop a clinically feasible 2D PC-MRI protocol for the
renal arteries on all clinical systems without the need for any
pulse-programming.
Limitations
Despite the corresponding authors of all previous renal PC-
MRI articles being contacted and invited to participate in this
consensus process, the number of panel members was rela-
tively small. However, the number should be seen in the con-
text of the size of the field. Moreover, the panel included
both scientists and clinicians from several international groups
that made significant contributions to the field of renal PC-
MRI. Other factors that may have influenced responses, such
as age, were not recorded, since the relatively small panel size
made it not possible to draw meaningful conclusions from
these additional parameters. Lastly, based on their back-
ground, renal PC-MRI type of usage, and specific expertise,
the panelists could have insufficient experience to agree or
disagree with specific consensus statements. To account for
this and avoid biasing the survey, panelists with insufficient
experience in any statement were asked to refrain from
answering.
Conclusion
This work provides a set of technical recommendations on
renal 2D PC-MRI acquisition, processing, and reporting,
developed by an international panel of experts through a con-
sensus process that should be taken into account when
starting new studies in the field of renal PC-MRI. The cur-
rent recommendations will promote more widespread adop-
tion of renal PC-MRI, will foster the initiation of multicenter
studies aimed at defining reference values and building larger
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and more definitive evidence of PC-MRI clinical validity, and
will ultimately allow a PC-MRI transfer to clinical practice to
improve the diagnosis and management of kidney diseases.
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